title: Long-term Clinical Outcome of Antibody Replacement Therapy in Humoral Immunodeficient Adults With Respiratory Tract Infections.
abstract: In severe humoral immunodeficiency the indication for antibody replacement therapy (ART) is clear, and supported by several large studies. However, for milder forms of humoral immunodeficiency, the indication for ART is less clear. This is a retrospective cohort study of 87 adults with recurrent respiratory tract infections who received ART. The patients had severe or mild humoral immunodeficiency, and were followed up for a median of 62months. Infection frequency, pharmacy-registered antibiotics use and hospital admissions significantly decreased under ART compared to the year prior to starting ART (median 5.50 (anamnestically)-0.82 (physician-confirmed) infections/year, p<0.001; median 4.00-2.05antibioticscourses/year, p<0.001; mean 0.75-0.44hospitaladmissions/year, p=0.009). These beneficial effects of ART were seen in both severe and mild immunodeficiency. Bronchiectasis was present in 27 patients when ART was started, but was not associated with clinical outcomes. An increase in hospital admissions under ART, observed in some patients, was significantly associated with pulmonary emphysema and current smoking. In conclusion, this study shows that ART is a long-term effective therapy in adults with recurrent respiratory tract infections with severe as well as with milder forms of humoral immunodeficiency.
authors.affiliation: Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands; Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands. Electronic address: d.kessel@antoniusziekenhuis.nl.
authors.forename: Diana A
authors.initials: DA
authors.lastname: van Kessel
authors.affiliation: Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands.
authors.forename: Thijs W
authors.initials: TW
authors.lastname: Hoffman
authors.affiliation: Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands.
authors.forename: Heleen
authors.initials: H
authors.lastname: van Velzen-Blad
authors.affiliation: Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands.
authors.forename: Pieter
authors.initials: P
authors.lastname: Zanen
authors.affiliation: Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands; Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands.
authors.forename: Jan C
authors.initials: JC
authors.lastname: Grutters
authors.affiliation: Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands; Department of Science, University College Roosevelt, Middelburg, The Netherlands.
authors.forename: Ger T
authors.initials: GT
authors.lastname: Rijkers
mesh_terms: D000368:Aged; D004417:Dyspnea / Q000209:etiology; D005260:Female; D006801:Humans; D056724:Immunity, Humoral; D016867:Immunocompromised Host; D007136:Immunoglobulins / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous
keywords: Gammaglobulin; Immunodeficiency; Immunoglobulin; Primary antibody deficiency; Respiratory tract infections